Related Experiment Videos
A role for phospholipase A2 in ARDS pathogenesis.
1Chargé de Recherche à l'Institut Pasteur, Unité de Pharmacologie Cellulaire, Unité Associée Institut Pasteur-INSERM no. 485, 25 rue Dr Roux, 75724 Paris Cedex 15, France. touqui@pasteur.fr
Molecular Medicine Today
|June 15, 1999
Summary
Acute respiratory distress syndrome (ARDS) involves lung injury and impaired gas exchange due to altered pulmonary surfactant. In ARDS, increased secretory phospholipase A2 (sPLA2-II) exacerbates this surfactant damage, creating a harmful cycle.
Area of Science:
- Pulmonary Medicine
- Biochemistry
Background:
- Acute respiratory distress syndrome (ARDS) is a severe lung injury.
- ARDS involves arterial hypoxemia and pulmonary edema.
- Pulmonary surfactant alterations impair gas exchange and cause alveolar collapse in ARDS.
Purpose of the Study:
- To discuss the role of secretory phospholipase A2 (sPLA2-II) in ARDS.
- To explain the mechanism of surfactant alteration in ARDS.
Main Methods:
- Literature review and evidence synthesis.
- Discussion of pathological pathways in ARDS.
Main Results:
- Secretory phospholipase A2 (sPLA2-II) hydrolyzes surfactant phospholipids.
- Surfactant normally inhibits sPLA2-II production.
- In ARDS, altered surfactant leads to increased sPLA2-II production.
Conclusions:
- Increased sPLA2-II exacerbates surfactant alteration in ARDS.
- This creates a vicious cycle of lung injury.
- Targeting sPLA2-II may offer therapeutic potential for ARDS.